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Integrins are a large family of heterodimeric transmembrane glycoprotein receptors, composed by two 
non-covalently-associated subunits (α and β). Integrins αVβ3 and αVβ5 have been found to be overexpressed 
on blood vessels in human tumors, but not on vessels in normal human tissues. For this reason, these 
integrins have become attractive targets for pharmacological studies mainly in the oncology area. The 
Gennari and Piarulli group recently developed a peptidomimetic compound (1) containing the RGD (Arg-
Gly-Asp) sequence and a diketopiperazine (DKP) scaffold as powerful αVβ3 integrin ligand.[1] A 
functionalized analogue of this ligand (2)[2] was linked to Paclitaxel through two lysosomally cleavable 
linkers (namely the Val-Ala and Phe-Lys peptide sequences).[3]  
 
 
 
 IC50 (nM)  
Structure CCRF-CEM (αvβ3 −) CCRF-CEM αvβ3 (αvβ3 +) Selectivity 
Paclitaxel 155 ± 55 21 ± 2 7.4 
RGD-Val-Ala-PTX (3) 5153 ± 977 77 ± 20 66.9 
RGD-Phe-Lys-PTX (4) 535 ± 70 34 ± 2 15.7 
Table 1: Antiproliferative activity of cyclo[DKP-RGD] conjugates in CCRF-CEM and 
CCRF-CEM αvβ3 after 6 hour-treatment followed by compound washout and 138 hour-
long growth in fresh medium. 
 
The resulting compounds 3 and 4 were subjected to stability assays in the presence of cathepsin B and 
lysosome extract, revealing that the free Paclitaxel is efficiently released under these conditions. The 
antiproliferative activities of the conjugates were evaluated against two isogenic cell lines expressing αVβ3 
at different levels: the acute lymphoblastic leukemia cell line CCRF-CEM (αVβ3 −) and its subclone CCRF-
CEM αVβ3 (αVβ3 +). A fairly effective integrin-targeting was displayed by conjugate 3, which was found to 
inhibit cell proliferation with increased selectivity towards αVβ3-expressing cells compared to the free PTX 
(Table 1).  
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